Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects

NCT ID: NCT03076385

Last Updated: 2022-04-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 201 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-12-31
• Study Completion Date: 2018-10-31

Brief Summary

This clinical study will assess the safety, tolerability and immunogenicity of VAL-506440 in healthy adult subjects.

Conditions

Influenza

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

VAL-506440

Group Type: EXPERIMENTAL

VAL-506440

Intervention Type: BIOLOGICAL

Escalating dose levels

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Interventions

VAL-506440

Escalating dose levels

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Agrees to comply with the study procedures and provides written informed consent
• 18 to 64 years of age
• Body mass index between 18 and 30 kg/m2
• Negative urine pregnancy test at the Screening visit and the day of each vaccination.
• Female subjects must either be of non-childbearing potential or use highly effective methods of contraception from at least 2 months before the Screening Visit through 3 weeks post last vaccination
• In good health based on medical history, physical examination, vital sign measurements and laboratory safety tests performed prior to initial study vaccination

Exclusion

• Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care
• Administration of an investigational product within 45 days
• Women who are pregnant or breastfeeding, or plan to become pregnant during the study
• Prior administration of investigational agent using formulations similar to VAL-506440
• History of a serious reaction to prior influenza vaccinations
• History of Guillain-Barré Syndrome within 6 weeks following a previous influenza vaccine
• Administration of any live attenuated vaccines within 4 weeks before enrollment, inactive vaccines within 2 weeks before enrollment, or plans to any vaccine within the vaccination period
• Any known or suspected immunosuppressive condition, acquired or congenital, as determined by history and/or physical examination
• Any chronic administration of immunosuppressant or other immune-modifying drugs within 6 months prior to administration of study vaccine
• Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.
• Any acute disease at the time of enrollment
• Any bleeding risk or thromboembolic event or any related medical history
• Regular alcohol consumption > 3 units/day, or current user of any illicit drugs, or has a history of drug/alcohol abuse with 1 year of screening or has a positive urine drug/alcohol test at screening
• Persons employed in a capacity that involves handling poultry or wild birds
• Unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies within 4 weeks before administration of the first vaccination, throughout the study
• Had major surgery or donation of blood or blood products within 4 weeks of dosing
• Current smoking of more than 10 cigarettes (or equivalent amount of tobacco) per day, and within 3 months prior to Screening
• Subject is an employee of the Sponsor or CRO involved in the study.
• Vulnerable subjects (e.g., a subject kept in detention).
• Any condition, that in the opinion of the Investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of the study results
• History of autoimmune disease
• Inadequate Liver Function as defined by AST, ALT, GGT, alkaline phosphatase and bilirubin > 1.5xULN
• Known allergy or history of anaphylaxis or other serious adverse reactions to any of the constituents of the study vaccine

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

ModernaTX, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Berlin, , Germany

Countries

Germany

References

Feldman RA, Fuhr R, Smolenov I, Mick Ribeiro A, Panther L, Watson M, Senn JJ, Smith M, Almarsson Ӧ, Pujar HS, Laska ME, Thompson J, Zaks T, Ciaramella G. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019 May 31;37(25):3326-3334. doi: 10.1016/j.vaccine.2019.04.074. Epub 2019 May 10.

Reference Type: DERIVED

PMID: 31079849 (View on PubMed)

Other Identifiers

2015-003452-48

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

VAL-506440-P101

Identifier Type: -

Identifier Source: org_study_id